ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1534

ANCA-associated Vasculitis Incidence in a Norther Spanish Health Region

Salma Al Fazazi1, Fabricio Benavides2, Alba Herrero-Morant3, Vanesa Calvo Río4, monica renuncio garcia2, clara escagedo Cagigas2, maria rodriguez Vidriales2 and Ricardo Blanco5, 1Hospital Universitario Puerta Del Mar, Cádiz, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, 4Valdecilla Hospital, Santander, Spain, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Meeting: ACR Convergence 2023

Keywords: ANCA associated vasculitis, Epidemiology, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1534–1553) Vasculitis – ANCA-Associated Poster II: Epidemiology, Outcomes, & Classification

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) includes granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) or microscopic polyarteritis (MPA). Precise estimation of the incidence of AAV has been difficult due to the absence of reliable diagnostic criteria.
To estimate the incidence in a Northern Spanish population-based cohort.

Methods: Population-based study of 132 patients diagnosed with small vessel vasculitis between 1994 and 2022 in a tertiary hospital. Finally, 98 patients were included as AAV according to ACR/EULAR 2022 criteria (1). Incidence was estimated by gender, age, and year of diagnosis.

Results: AAV was diagnosed in 98 (49 women/ 49 men) patients: GPA (n=47, 48%) MPA (n=37,37.8%) and EGPA (n=14, 14.3%). Annual incidences were estimated in AAV (Figure). GPA annual incidence in our population area in the 1994-2022 period was 2.81 per 1,000,000 people, 95% CI: 3.77-1.85 (2.82 [4.35-1.29] in males and 2.80 [4.50-1.09] in females). An upward trend in annual incidence over time was observed with rates ranging from 1.88 in 1994 to 6.84 in 2022 (weak correlation; r 2=0.2729). On the other hand, MPA annual incidence was 2.23 per 1,000,000 people (1.92 [3.55-0.27] in males and 2.46 [4.07-0.85] in females). Rates ranged from 1.88 in 1994 to 1.71 in 2022 with an upward trend over time (very weak correlation; r 2=0.0746). In the case of GEPA, annual incidence was 0.83 per 1,000,000 people, 95% CI: 1.72-0.06 (1.22 [2.74-0.30] in males and 0.46 [2.29-1.37] in females). As in the other types of AAV, there was an upward trend over time with variations of from 1.88 in 1999 to 3.42 in 2022 (weak correlation; r 2=0.3335). A comparison between different geographical areas is summarized in Table. Wide variations in annual incidence per million were observed in all AAV (GPA 2.1-34; MPA 2.23-10.4; EGPA 0.64-2.7). The highest annual incidence of all AAV was observed in nordic countries and central Europe while the lowest in Southern Europe.

Conclusion: There seems to be a progressive increase in incidence of AAV over the years in the studied population. Annual incidence in our population was similar to that of other southern European countries.

Supporting image 1

Figure . Annual incidence of AAV in 1994_2022.

Supporting image 2

Table. AAV incidence cases reported in the literature.


Disclosures: S. Al Fazazi: None; F. Benavides: None; A. Herrero-Morant: None; V. Calvo Río: None; m. renuncio garcia: None; c. escagedo Cagigas: None; m. rodriguez Vidriales: None; R. Blanco: AbbVie, 5, 6, Amgen, 6, AstraZeneca, 2, BMS, 6, Eli Lilly, 6, Galapagos, 2, 6, Janssen, 2, 6, MSD, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 5, 6, Sanofi, 6.

To cite this abstract in AMA style:

Al Fazazi S, Benavides F, Herrero-Morant A, Calvo Río V, renuncio garcia m, escagedo Cagigas c, rodriguez Vidriales m, Blanco R. ANCA-associated Vasculitis Incidence in a Norther Spanish Health Region [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/anca-associated-vasculitis-incidence-in-a-norther-spanish-health-region/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anca-associated-vasculitis-incidence-in-a-norther-spanish-health-region/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology